Inflammatix Secures $57 Million in Series E Funding for TriVerity Test Commercialization

Inflammatix, a molecular diagnostics company based in Sunnyvale, California, has successfully closed a $57 million Series E financing round led by Khosla Ventures and Think.Health. The funding will be utilized to support regulatory filing and early commercialization of their lead product, the TriVerity™ Acute Infection and Sepsis Test (TriVerity). This innovative blood test aims to address the critical need for accurate and timely diagnosis of acute infections and sepsis in emergency department settings.

Dr. Timothy Sweeney, the CEO and cofounder of Inflammatix, expressed gratitude for the investor confidence in TriVerity, highlighting the potential impact of the test on improving patient care and hospital efficiency. The funds will help expand the commercial team, plan clinical studies, and await FDA clearance, which is expected in the coming months.

Apart from Khosla Ventures and Think.Health, notable investors in the Series E funding round include Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital, OSF Healthcare, RAW Ventures, among others. This successful round brings Inflammatixs total private capital raised to over $200 million, in addition to significant grants and contracts received from government agencies and foundations.

The TriVerity Test, designed to be performed on Inflammatixs Myrna™ Instrument, represents a novel diagnostic approach utilizing machine learning and AI to detect RNA changes in immune cells indicative of infection and sepsis. The ultimate goal is to enable faster and more accurate diagnoses, potentially saving lives, improving hospital efficiency, and aiding healthcare providers in complying with sepsis detection and treatment protocols.

By securing Breakthrough Device Designation from the FDA and completing the SEPSISSHIELD study, Inflammatix recently submitted a regulatory packet for the TriVerity Test with hopes of FDA clearance later this year.